ClinicalTrials.gg
CompletedNCT04115319Updated Dec 31, 2025Results posted

A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.

A Phase 3 interventional study of SEP363856 and quetiapine XR in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 42 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
305
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing SEP-363856 in Schizophrenia — 1 open to participants now, 2 under way, 2 of them phase 3. SEP-363856 · Schizophrenia.

Enrollment
5th of 23
305 · median 83
Started
2019
with 4 others
Phase 3
9 of 23
1 open now
Registered
10th of 23
by date
Lead sponsor
18 of 23
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 23 studies testing SEP-363856 in Schizophrenia, this one is the 5th largest by enrollment, is one of 5 that started in 2019, is one of 9 in phase 3, and was the 10th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 23 studies testing SEP-363856 in Schizophrenia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About SEP-363856

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing SEP-363856 in Schizophrenia, or all of them as a file.
02

Study summary

A clinical study to evaluate the long-term safety and tolerability of an investigational drug in people with schizophrenia.

This study is accepting male and female participants between 18 years old -65 years old who have been diagnosed with schizophrenia. This study will be conducted in approximately 50 study centers worldwide. The study will last approximately 57 weeks.

Read the detailed description

This is a 52-week, multicenter, randomized, double-blind, parallel-group, flexible-dose study designed to evaluate the long-term safety and tolerability of SEP-363856 (50 to 100 mg/day) compared with quetiapine XR (400 to 800 mg/day) in clinically stable adult participants with schizophrenia. This study is projected to randomize a least 300 participants to two treatment groups (SEP-363856 50 to 100 mg/day or quetiapine XR 400 to 800 mg/day) in a 2:1 ratio. Study drug will be taken once a day and may be taken without food or with a light meal.

Sumitomo Pharma America Inc. was the former Sponsor and conducted this study. Sumitomo was responsible for analysis and clinical study report (CSR) completion. Otsuka took over study after IND was transferred and is concluding activities with registry postings.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • schizophrenia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include, but are not limited to the following:

  • Male or female participant between 18 to 65 years of age (inclusive) at the time of consent.
  • Participant meets criteria for a diagnosis of schizophrenia as established by clinical interview at screening (using the DSM-5 as a reference and confirmed using the SCID-CT). The time since the participant's diagnosis must be ≥ 1 year prior to Screening.
  • Participant must have a CGI-S score ≤ 4 at Screening and Baseline.
  • Participant must have a PANSS total score ≤ 80 at Screening and Baseline.
  • Participant is judged to be clinically stable (i.e., no evidence of an acute exacerbation) by the Investigator for at least 8 weeks prior to Screening.
  • Participant has had no change in antipsychotic medication(s) (minor dose adjustments for tolerability purposes are permitted) for at least 6 weeks prior to Screening.
  • Participants taking an antipsychotic agent at Screening may participate in this study only if there are signs of intolerability or lack of efficacy of the current antipsychotic (as determined by the Investigator).
  • Participant is, in the opinion of the Investigator, generally healthy based on Screening medical history, PE, neurological examination, vital signs, (ECG) and clinical laboratory values (hematology, chemistry and urinalysis).

Exclusion criteria

Exclusion criteria:

Main exclusion criteria include, but are not limited to:

  • Participant was hospitalized for a psychiatric illness within the 8 weeks prior to Screening.
  • Participant has a current diagnosis or presence of symptoms consistent with a DSM-5 diagnosis other than schizophrenia. Exclusionary disorders include but are not limited to alcohol use disorder (within past 12 months), substance (other than nicotine or caffeine) use disorder within past 12 months, or lifetime history of significant substance abuse that, in the opinion of the Investigator or Sponsor, may have had a significant and potentially permanent impact on the brain or other body systems, major depressive disorder, schizoaffective disorder, ,bipolar I or II disorder, obsessive compulsive disorder, and posttraumatic stress disorder, symptoms of mild to moderate mood dysphoria or anxiety are allowed so long as theses symptoms are not the primary focus of treatment.
  • Participant is judged to be resistant to antipsychotic treatment by the Investigator, based on failure to respond to 2 or more marketed antipsychotic agents within a 1-year period prior to Screening, given at adequate dose as per labeling, for at least 4 weeks.
  • Participant answers "yes" to "Suicidal Ideation" Item 4 (active suicidal ideation with some intent to act, without specific plan) or Item 5 (active suicidal ideation with specific plan and intent) on the C-SSRS assessment at Screening (i.e., in the past one month) or at Baseline (i.e., since last visit).
  • Participant is at significant risk of harming self or others based on Investigator's judgment.
  • Participant has attempted suicide within 6 months prior to Screening.
  • Participant has received treatment with a psychotropic medication or herbal supplement within 3 days or 5 half-lives (whichever is longer)
  • Participant has been treated with quetiapine or quetiapine XR within the 6 weeks prior to Screening or has a history of inadequate response or intolerability to quetiapine or quetiapine XR.
  • Participant has any unstable medical condition or any clinically significant chronic disease that in the opinion of the Investigator, would limit the participant's ability to complete and/or participate in the study.
  • Participant has any clinically significant abnormal laboratory value(s) at Screening as determined by investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
305 participants (actual)

Study arms

  • Experimental
    SEP363856

    SEP363856 50mg, 75mg, 100mg, flexibly dosed once daily capsule

    Drug: SEP363856

  • Active comparator
    quetiapine XR

    quetiapine XR, 400, 600, 800 mg, flexibly dosed once daily capsule

    Drug: quetiapine XR

Interventions

  • SEP-363856, 50mg, 75mg, 100mg, flexibly dosed once daily capsule

  • quetiapine XR, 400, 600, 800 mg, flexibly dosed once daily capsule

    Also known as: Seroquel XR

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Study Discontinuation

    An AE was any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Untoward medical occurrences that occured after first administration of study drug were considered AEs. A SAE is an AE that meets one or more criteria: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, or is a congenital anomaly or birth defect.

    Time frame: From first dose of the study drug up to 7 days after last dose of study drug (Up to 53 weeks)

07

Results

Posted Dec 31, 2025

Participant flow

Participants took part in the study at investigational sites in Russia, US, Romania and Ukraine from 21 Nov 2019 to 30 Dec 2022.

Participant flow — Overall Study
MilestoneSEP-363856 50 to 100 mg/DayQuetiapine XR 400 to 800 mg/Day
Started203102
Completed10557
Not completed9845
Withdrew: Randomized, but withdrawn from study prior to treatment20
Withdrew: Withdrawal by participant179
Withdrew: Geopolitical conflict related21
Withdrew: Covid-19 related10
Withdrew: Adverse event4821
Withdrew: Noncompliance with study drug51
Withdrew: Lack of efficacy62
Withdrew: Lost to follow-up67
Withdrew: Protocol deviation51
Withdrew: Participant relocated52
Withdrew: Personal reasons01
Withdrew: Deemed unsuitable for participation10

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Study Discontinuation

An AE was any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Untoward medical occurrences that occured after first administration of study drug were considered AEs. A SAE is an AE that meets one or more criteria: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, or is a congenital anomaly or birth defect.

Time frame:
From first dose of the study drug up to 7 days after last dose of study drug (Up to 53 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Study Discontinuation
ParticipantsSEP-363856 50 to 100 mg/DayQuetiapine XR 400 to 800 mg/Day
AEs15377
SAEs160
AEs Leading to Trial Discontinuation4821

Adverse events

Collected over From first dose of the study drug up to 7 days after last dose of study drug (Up to 53 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SEP-363856 50 to 100 mg/Day0/201 (0%)16/201 (8%)103/201 (51.2%)
Quetiapine XR 400 to 800 mg/Day0/102 (0%)0/102 (0%)55/102 (53.9%)
Most frequent serious events
Most frequent serious events
EventSEP-363856 50 to 100 mg/DayQuetiapine XR 400 to 800 mg/Day
SchizophreniaPsychiatric disorders10/2010/102
Suicide attemptPsychiatric disorders2/2010/102
Multiple injuriesInjury, poisoning and procedural complications2/2010/102
AnxietyPsychiatric disorders1/2010/102
Cerebrovascular accidentNervous system disorders1/2010/102
FallInjury, poisoning and procedural complications1/2010/102
Limb injuryInjury, poisoning and procedural complications1/2010/102
Corona virus infectionInfections and infestations1/2010/102
Most frequent other events
Showing 10 of 12
Most frequent other events
EventSEP-363856 50 to 100 mg/DayQuetiapine XR 400 to 800 mg/Day
SomnolenceNervous system disorders12/20121/102
InsomniaPsychiatric disorders30/20111/102
AnxietyPsychiatric disorders27/20110/102
ConstipationGastrointestinal disorders7/20112/102
Weight increasedInvestigations9/20111/102
SchizophreniaPsychiatric disorders21/2016/102
HeadacheNervous system disorders20/2018/102
AstheniaGeneral disorders5/2019/102
DizzinessNervous system disorders16/2015/102
AkathisiaNervous system disorders14/2012/102

Baseline characteristics

Safety population included all participants that were enrolled and received at least 1 dose of study drug during the 52-week treatment period.

Age, Continuous
Age, Continuous(years)SEP-363856 50 to 100 mg/DayQuetiapine XR 400 to 800 mg/DayTotal
Mean40.3 ± 11.7738.4 ± 12.6639.7 ± 12.09
Sex: Female, Male
Sex: Female, Male(Participants)SEP-363856 50 to 100 mg/DayQuetiapine XR 400 to 800 mg/DayTotal
Female8837125
Male11365178
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SEP-363856 50 to 100 mg/DayQuetiapine XR 400 to 800 mg/DayTotal
Hispanic or Latino8412
Not Hispanic or Latino19398291
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SEP-363856 50 to 100 mg/DayQuetiapine XR 400 to 800 mg/DayTotal
American Indian or Alaska Native202
Asian202
Native Hawaiian or Other Pacific Islander000
Black or African American472875
White15073223
More than one race000
Unknown or Not Reported011
Region of Enrollment
Region of Enrollment(Participants)SEP-363856 50 to 100 mg/DayQuetiapine XR 400 to 800 mg/DayTotal
Romania213
United States7439113
Ukraine422163
Russia8341124
08

Study locations

42 sites
  • Research Site
    Cerritos, California 90703, United States
  • Research Site
    Oakland, California 94607, United States
  • Research Site
    Oceanside, California 92056, United States
  • Research Site
    San Diego, California 92103, United States
  • Research Site
    Torrance, California 90502, United States
  • Research Site
    Miami, Florida 33122, United States
  • Research Site
    Miami Lakes, Florida 33016, United States
  • Research Site
    Atlanta, Georgia 30328, United States
  • Research Site
    Hoffman Estates, Illinois 60169, United States
  • Research Site
    Lincolnwood, Illinois 60712, United States
  • Research Site
    Shreveport, Louisiana 71101, United States
  • Research Site
    St Louis, Missouri 63128, United States
  • Research Site
    Las Vegas, Nevada 89102, United States
  • Research Site
    Cedarhurst, New York 11516, United States
  • Research Site
    Jamaica, New York 11432, United States
  • Research Site
    Rochester, New York 14618, United States
  • Research Site
    Charlotte, North Carolina 28211, United States
  • Research Site
    North Canton, Ohio 44720, United States
  • Research Site
    Brasov, 500079, Romania
  • Research Site
    Bucharest, 041914, Romania
  • Research Site
    Bucharest, 060222, Romania
  • Research Site
    Bucharest, 41914,, Romania
  • Research Site
    Iași, 700282, Romania
  • Research Site
    Arkhangelsk, 163530, Russia
  • Research Site
    Moscow, 127083, Russia
  • Research Site
    Omsk, 644070, Russia
  • Research Site
    Saint Petersburg, 188357, Russia
  • Research Site
    Saint Petersburg, 190121, Russia
  • Research Site
    Saint Petersburg, 192019, Russia
  • Research Site
    Saint Petersburg, 195176, Russia
  • Research Site
    Saint Petersburg, 199106, Russia
  • Research Site
    Smolensk, 214031, Russia
  • Research Site
    Stavropol, 357034, Russia
  • Research Site
    Tomsk, 634014, Russia
  • Research Site
    Yaroslavl, 150003, Russia
  • Research Site
    Yekaterinburg, 620030, Russia
  • Research Site
    Ivano-Frankivsk, 76011, Ukraine
  • Research Site
    Kharkiv, 61068, Ukraine
  • Research Site
    Kyiv, 03049, Ukraine
  • Research Site
    Smila, 20708, Ukraine
  • Research Site
    Ternopil, 46027, Ukraine
  • Research Site
    Uzhhorod, 88000, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Dec 2022, 37 months.

Results were first posted in Dec 2025, 3 years after primary completion. A results delay was requested in Dec 2023.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 37 months is above that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2019
First posted
Oct 4, 2019
StartActual
Nov 21, 2019
Primary completionActual
Dec 30, 2022
CompletionActual
Dec 30, 2022
Results delay requested
Dec 13, 2023
Results first posted
Dec 31, 2025
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04115319
Responsible party
Sponsor
First posted
Oct 4, 2019
Start date
Nov 21, 2019
Primary completion
Dec 30, 2022
Completion
Dec 30, 2022
Results posted
Dec 31, 2025
Last update
Dec 31, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SEP-363856

Start the discussion